Doxycycline (DBL) is a medicine containing the active ingredient(s) doxycycline. On this page you will find out more about Doxycycline (DBL), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: doxycycline
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Doxycycline (DBL) 50 mg modified release capsule, 25
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. Doxycycline is active against a wide range of gram-positive and gram-negative organisms. NOTE: THE 50 mg CAPSULE IS NOT A PAEDIATRIC FORMULATION. MAYNE PHARMA Doxycycline Capsules are indicated in the treatment of infections caused by the following micro-organisms: Mycoplasma pneumoniae: primary atypical pneumonia. Rickettsiae: Queensland tick typhus, typhus fever and Q fever. Agents of psittacosis. Calymmatobacterium (Donovania) granulomitis: granuloma inguinale. Agents of lymphogranuloma venereum. Borreliae: relapsing fever. Chlamydia trachomatis. MAYNE PHARMA Doxycycline Capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral Doxycycline Capsules alone, or in combination with topical agents. MAYNE PHARMA Doxycycline is indicated in the treatment of infections caused by the following Gram-negative micro-organisms: Vibrio species: cholera. Brucella species: brucellosis (in conjunction with streptomycin). Yersinia pestis: plague. Francisella tularensis: tularemia. Bartonella bacilliformis: Bartonellosis. Bacteroides species. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Treponema pallidum: syphilis. Treponema pertenue: yaws. Neisseria gonorrhoea: gonorrhoea (see Dosage and Administration). MAYNE PHARMA Doxycycline Capsules is not the drug of choice in the treatment of any type of Staphylococcal infection or infections caused by Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. Doxycycline should not be used in these infections unless the organism has been shown to be sensitive. For upper respiratory tract infections due to group A beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. Doxycycline is active against both pre-erythroycitic and asexual bloodstages of Plasmodium falciparum. The tetracyclines are only partially active against the pre-erythrocytic stages of Plasmodium vivax and protection depends on drug suppression of the blood stages. Doxycycline has no activity against the relapsing forms (hypnozoites) of Plasmodium vivax. Doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by Plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by Plasmodium vivax. Doxycycline is only able to suppress malaria caused by P. vivax. As there are relatively few locations where P. vivax does not co-exist to some extent with P. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. In acute intestinal amoebiasis MANYE PHARMA Doxycycline Capsules may be a useful adjunct to amoebicides. In severe acne MAYNE PHARMA Doxycycline Capsules may be a useful adjunctive therapy
Table of characteristics
Hard gelatin capsules, size 4, printed Doxy 50 in black and filled with yellow spheroidal pellets.
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Capsule, modified release|
|Route of administration||Oral|
25: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||24 Months|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.